SCHEMBL7464992

SCHEMBL7464992

O=C1c2ccccc2-c2nc3ccccc3cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 1.00
NPC1 O15118 4/20 1.00
MAPT P10636 7/20 0.60
SMN1; SMN2 Q16637 5/20 0.60
ALDH1A1 P00352 4/20 0.60
AHR P35869 1/20 0.60
ATM Q13315 1/20 0.58
MAOB P27338 4/20 0.49
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
KDM4E B2RXH2 3/20 0.49
TP53 P04637 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
HSD17B10 Q99714 2/20 0.49
PKM P14618 2/20 0.47
MAPK1 P28482 2/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31538695 1.00 RAB9A (1.00) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL18462381 0.96 RAB9A (0.93) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL7648567 0.92 RAB9A (0.86) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
Anthraquinone SCHEMBL8972708 0.84 NPC1 (0.71) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL14380264 0.84 RAB9A (0.71) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL824427 0.75 RAB9A (1.00) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL2681287 0.74 RAB9A (0.74) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
Anthraquinone SCHEMBL5550279 0.74 MAPT (0.67) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL30327427 0.74 MEN1 (0.67) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL236156 0.74 MEN1 (0.67) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11145824-B2 Organic photoelectric functional material, method for preparing the same, use of the same, organic electronic assembly, and light-emitting device AAC MICROTECH(CHANGZHOU)CO., LTD. (CN) 2021-10-12 US disclosed
US-10370473-B2 Compound, curable composition, cured product, optical member, and lens FUJIFILM CORPORATION (JP) 2019-08-06 US disclosed
US-20190237678-A1 ORGANIC PHOTOELECTRIC FUNCTIONAL MATERIAL, METHOD FOR PREPARING THE SAME, USE OF THE SAME, ORGANIC ELECTRONIC ASSEMBLY, AND LIGHT-EMITTING DEVICE Nanjing Tech Universiy (CN) 2019-08-01 US disclosed
EP-0785191-B1 FUSED INDAN DERIVATIVES AND SALTS THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2002-10-23 EP disclosed
EP-0785191-A1 FUSED INDAN DERIVATIVES AND SALTS THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 1997-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190237678-A1 ORGANIC PHOTOELECTRIC FUNCTIONAL MATERIAL, METHOD FOR PREPARING THE SAME, USE OF THE SAME, ORGANIC ELECTRONIC ASSEMBLY, AND LIGHT-EMITTING DEVICE FARS2, PPOX, ETFA RAB9A 2488/4885NPC1 3420/4885MAPT 3556/4885
US-10370473-B2 Compound, curable composition, cured product, optical member, and lens CRYZ, CRYAA, UACA RAB9A 1738/4885NPC1 2312/4885MAPT 1248/4885
US-11145824-B2 Organic photoelectric functional material, method for preparing the same, use of the same, organic electronic assembly, and light-emitting device FARS2, PPOX, ETFA RAB9A 2488/4885NPC1 3420/4885MAPT 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.